BSH 2022 | Unmet need in hemophilia A: breakthrough bleeds
Eman Hassan, MD, Birmingham Children’s Hospital, Birmingham, UK, talks on breakthrough bleeds in hemophilia A. Indeed, despite the effectiveness of emicizumab prophylaxis, some patients still experience breakthrough bleeds. Dr Hassan explains that today, the aim is to achieve zero bleeding, so that patients with hemophilia A can lead a normal lifestyle without being limited by the disease. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
Transcript (edited for clarity)
Still, a target in treating hemophilia A patients is transforming their life into zero bleeding life, but, even on emicizumab prophylaxis, breakthrough bleeds can still occur. So, although they are rare, they are still occurring. So our target and our aim is to change their life totally into zero bleeding life and to be normal, a person performing all types of sport, to be effective in the community without any restrictions at all...
Still, a target in treating hemophilia A patients is transforming their life into zero bleeding life, but, even on emicizumab prophylaxis, breakthrough bleeds can still occur. So, although they are rare, they are still occurring. So our target and our aim is to change their life totally into zero bleeding life and to be normal, a person performing all types of sport, to be effective in the community without any restrictions at all. This is the unmet need that the breakthrough bleeds still occur in patients with severe hemophilia A.
Read more...
